Articles related to PATIENT ADHERENCE

Conference presenters highlighted gaps in menopause medication coverage and follow-up support, describing opportunities for pharmacist involvement while offering no comparative evidence that employer-sponsored programs improve symptoms, adherence, or workplace outcomes.

The FDA has approved once-monthly subcutaneous olanzapine for adults with schizophrenia, supported by placebo-controlled trial data showing symptom improvement and sustained efficacy through 48 weeks, while eliminating several logistical requirements associated with treatment initiation.

Low-dose (Z)-endoxifen significantly reduced mammographic breast density in premenopausal women while producing fewer treatment-related symptoms than expected with standard tamoxifen exposure. The phase II findings suggest a potential new prevention strategy, but effects on actual breast cancer incidence remain unknown.

The FDA approved a low-estrogen weekly contraceptive patch for pregnancy prevention in eligible women with BMI below 30 kg/m². Approval was supported by Phase 3 efficacy, safety, and adhesion data, but use remains subject to established combined hormonal contraceptive contraindications.

A post-thyroidectomy patient’s LDL-C rose above 250 mg/dL during recurrent hypothyroidism and improved after euthyroidism returned. The case highlights medication adherence and secondary-cause review before lipid-therapy escalation.

A network meta-analysis of 716 randomized trials and 159,362 participants found ARB-based regimens had the lowest rates of treatment discontinuation due to adverse effects, with the ARB-CCB combination ranking as the best-tolerated dual-drug option among antihypertensive regimens examined.